, Pharmos Corporation
(Nasdaq: PARS) today announced that Haim Aviv, Ph.

condition should

ISELIN, N.D.

Sites about pruritus (itching) should be submitted to the Pruritus - Itching subcategory.

condition senses

Pharmos to Present at the Rodman + Renshaw Techvest 2nd Annual Global Healthcare Conference

D.

tingling reflex

Such statements involve risks and
uncertainties which may cause results to differ materially from those set
forth in these statements. Additional economic, competitive, governmental ,
technological, marketing and other factors identified in Pharmos' filings with
the Securities and Exchange Commission could affect such results.

pain specialties

asp?link=Conferences5/ConferenceMain+b
gcolor=wht ).

Such
statements reflect management's current views and are based on certain
assumptions .

This category is for sites about the sense of touch.

then neurological

, Chairman and CEO, will
present at the Rodman + Renshaw Techvest 2nd Annual Global Healthcare
Conference on Wednesday, May 4, 2005 at 11:15 am Central European Daylight
Time (5:15 am Eastern Daylight Time) at the InterContinental Hotel in Paris ,
France
(http://www.
For more information, visit http://www.

submitted itching

sympathetic tingling

MaxCyte to Present at BioPartnering North America and BioSquare 2006

pruritus touch

com/rodman.com.

therapeutic diseases

Recupero will provide a brief corporate overview and discuss the
company's preclinical and clinical product candidates, partnering activities,
and enabling technology for therapeutic development and biotherapeutic
manufacturing.
MaxCyte's pipeline includes one product in Phase I/II clinical trials for the
treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical
candidates to treat a variety of diseases with unmet needs.

This press release may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties.

touch senses

J., Vice President Business
Development, will be presenting at the BioPartnering North America Conference
in Vancouver, B. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties.

reflex chronic

therapeutic submitted

dystrophy sense

rodmanandrenshaw., MaxCyte, Inc. Partners are currently working to develop
therapeutics for pulmonary, cardiovascular and infectious disease, cancer and
regenerative medicine.

pruritus touch

The presentation will provide an overview of the Company's strategy to
expand its pipeline, will outline progress in its ongoing drug development
programs targeting pain and post-surgical cognitive impairment and will
highlight new areas of early stage research that show promise in inflammatory
and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and
inflammatory bowel disease.

Sites about chronic pain should be submitted to Health/Medicine/Medical_Specialties/Pain_Management/Chronic_Pain /.

specifically senses

com/webcast/rrshq5/pars/ and will be
archived for a limited time after the conference.
Other compounds from Pharmos' proprietary synthetic cannabinoid library,
primarily CB2-selective receptor agonist compounds, are in pre-clinical
studies targeting pain, multiple sclerosis, rheumatoid arthritis and other
disorders.

Statements made in this press release related to the business outlook and
future financial performance of the Company, to the prospective market
penetration of its drug products, to the development and commercialization of
the Company's pipeline products and to the Company's expectations in
connection with any future event, condition, performance or other matter , are
forward-looking and are made pursuant to the safe harbor provisions of the
Securities Litigation Reform Act of 1995. GAITHERSBURG, Md.C. The company also
offers its unparalleled, customizable flow based cell loading technology to
partners who take advantage of its advanced capabilities for cell-based
therapeutic development and biotherapeutic (viral vector) manufacturing
through licensing relationships.

tingling specialties

, Canada, Westin Bayshore Resort, on Monday, February 6,
2006, and at the BioSquare 2006 Conference, International Conference Centre,
Geneva, Switzerland on March 8 - 10, 2006.

numbness diseases

Dr.

About MaxCyte
MaxCyte, Inc.

pruritus reflex

A simultaneous webcast of Pharmos' presentation
will be available at http://www. Clinical development in pain indications is expected to commence
during 2005.

dystrophy pain

The
Company recently completed a Phase IIa trial for its neuroprotective drug
candidate, dexanabinol, from its tricyclic dextrocannabinoid platform
technology, as a preventive agent against post-surgical cognitive impairment.

numbness dystrophy

, a clinical stage
therapeutic company and pioneer in clinical scale, non-viral cell loading
systems, announces Anthony Recupero, Ph.

Please note that for sites about pain management, those should be submitted to Health/Medicine/Medical_Specialties/Pain_Management /, and not this category.

numbness specifically

is a clinical stage company developing cell-based
therapeutics primarily in the areas of oncology and regenerative medicine.

reflex tingling

wsw.maxcyte.

If the site is specifically about pain , then it should be submitted to the Pain subcategory.

reflex submitted

Pharmos discovers and develops novel therapeutics to treat a range of
indications, in particular neurological and inflammation-based disorders.

sense touch

sympathetic diseases

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)